Alberto Montero is an Oncology physician affiliated with University Hospitals of Cleveland. OpenAlex indexes 330 publications with 8,125 citations (h-index 44); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-3951Provider last certified this registry record 7 Dec 2020.
Clinical trials
- Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
Sponsor: Janssen Diagnostics, LLC
- Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Sponsor: AEterna Zentaris
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Genentech USA, Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.2%Aromatase Inhibitor36.7%Anastrozole77%Exemestane23%Part D<11 patientsKinase inhibitor35.9%Ibrance87%Kisqali13%Part D<11 patients+ 1 more class in this area
Nervous system
11%Gabapentinoids5.9%Pregabalin100%Part D<11 patientsOpioid Agonist5.1%Oxycodone Hcl100%Part D<11 patientsMetabolism & gastrointestinal
6.8%Serotonin-3 Receptor Antagonist6.8%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2014–2014 per NIH RePORTER. The latest:
- Enhancing T-Cell Responses with the Glutathione Mimetic NOV-002 in Breast Cancer
Cleveland Clinic Lerner Com-Cwru
FY2014$159,614K23CA148893
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Sophia Sundararajan, MD
University Hospitals of Cleveland
Sylvia Asa, MD, PhD
University Hospitals of Cleveland
Lloyd Greene, MD
University Hospitals of Cleveland
Hans Luders
University Hospitals of Cleveland
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”